Regular ArticleEVI1 Is Expressed in Megakaryocyte Cell Lineage and Enforced Expression of EVI1 in UT-7/GM Cells Induces Megakaryocyte Differentiation☆
References (41)
- et al.
Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines
Cell
(1988) - et al.
Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26)
Blood
(1994) - et al.
Characterization of a factor-dependent acute leukemia cell line with translocation (3;3)(q21;q26)
Blood
(1990) - et al.
In vitro development of erythroid and megakaryocytic cells from a UT-7 subline, UT-7/GM
Blood
(1997) - et al.
Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo derived from human leukemia cell line, UT-7
Blood
(1993) - et al.
Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO
Blood
(1996) - et al.
The role of neutrophil membrane glycoprotein GP-150 in neutrophil adherence to endothelium in vitro
Blood
(1985) - et al.
The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia
Blood
(1995) - et al.
Consequences of GATA-1 deficiency in megakaryocytes and platelets
Blood
(1999) - et al.
Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes
Blood
(1998)
The tissue-specific transcriptional regulation of the megakaryocytic glycoprotein IIb gene is controlled by interactions between a repressor and positive cis-acting elements
Blood
Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes
Blood
EVI1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain
J. Biol. Chem.
Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes
Blood
Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization
Blood
Identification of a common ecotropic viral integration site, EVI1, in the DNA of AKXD murine myeloid tumors
Mol. Cell. Biol.
Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26
Proc. Natl. Acad. Sci. USA
EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia
Leukemia
Generation of the AML1-EVI1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia
EMBO J.
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations
Proc. Natl. Acad. Sci. USA
Cited by (34)
Integrating transcription-factor abundance with chromatin accessibility in human erythroid lineage commitment
2022, Cell Reports MethodsCitation Excerpt :The binding motifs for these two TFs also exhibited strong differences in accessibility between GATA-1-high and GATA-1-mid/low progenitors (Figure 2C). We further observed a broader trend of increased accessibility surrounding the motifs for TFs that drive erythroid fates (e.g., GATA-1, Mecom [Shimizu et al., 2002]) and decreased accessibility at motifs for TFs that drive myeloid and lymphoid lineages (e.g., SPI1 [Hromas et al., 1993; Klemsz et al., 1990], EBF1 [Nechanitzky et al., 2013]) in GATA-1-high progenitors (Figure 2C). Analysis of differentially accessible peaks showed enrichment of these erythroid TF motifs in sites more accessible in GATA-1-high progenitors and enrichment of a variety of myeloid and lymphoid TFs in sites more accessible in GATA-1-mid/low-expressing progenitors (Figures 2D, 2E, and S2C).
Retroviral integrations in gene therapy trials
2012, Molecular TherapyCitation Excerpt :This feature is of particular relevance for MLV vectors which, in absence of any strong in vivo clonal selection, display a tendency to land into certain stem cell associated loci in vitro due to the transcriptional activity and epigenetic status of hematopoietic progenitors at the time of transduction.20,51 These insertional preferences could explain why different GT trials, irrespectively to their outcomes, displayed the same vector bias for genomic regions like LMO2 and EVI1, which are highly active in hematopoietic progenitors.56,57 Indeed, by tracking LMO2 integrations overtime in different patients from our ADA-SCID GT trial, we showed that the relative clonal contribution of these integrants was maintained below 1% of all transduced T cells over a long period of time after GT.19
Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1 <sup>high</sup> leukemia cells
2011, Biochemical and Biophysical Research CommunicationsCitation Excerpt :The gene expression profiles of EVI1high AML patients are quite similar to those of control CD34+ cells [6], and furthermore, analysis of EVI1-deficient mice has shown that EVI1 is required for the maintenance of hematopoietic stem cells (HSCs), suggesting that EVI1high leukemia cells may have stem cell-like phenotypes. We and other groups have shown that EVI1 is predominantly expressed both in embryonic HSCs and HSCs in adult bone marrow [8–10]. EVI1 maintains the self-renewal capacity of embryonic HSCs by activating Gata2 transcription [11], and ablation of EVI1 in adult bone marrow also leads to a significant decrease in HSCs [12].
- ☆
Work was supported in part by Grants-in-Aid from the Ministry of Health and Welfare.
- 1
To whom correspondence and reprint requests should be addressed at Department of Biochemistry, Miyazaki Medical College, 5200 Kihara, Miyazaki-Gun, Miyazaki-Ken 889-1692, Japan. Fax: 81-985-85-2401. E-mail: [email protected].